Actively Recruiting
Phase III Study Comparing BL-B01D1 Plus Anti-PD-1 Antibody Versus Nab-paclitaxel Plus Anti-PD-1 Antibody in Women With Previously Untreated Advanced or Metastatic Triple-Negative Breast Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-09-30
436
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of BL-B01D1 combined with a PD-1 monoclonal antibody compared to nab-paclitaxel combined with a PD-1 monoclonal antibody in women with PD-L1-positive, previously untreated, locally advanced, inoperable, or metastatic triple-negative breast cancer. This Phase III randomized, open-label, multicenter study aims to provide important information about treatment options for this condition. Participants are randomly assigned to receive either BL-B01D1 plus a PD-1 monoclonal antibody or nab-paclitaxel plus a PD-1 monoclonal antibody. Each treatment cycle lasts 3 weeks, with additional cycles provided if participants show clinical benefit. Treatment continues until disease progression, intolerable side effects, or other reasons for stopping. During the study, participants undergo regular assessments including imaging to measure tumor response, safety monitoring, and laboratory tests. Researchers will measure progression-free survival and overall survival up to approximately 24 months. Other evaluations include treatment response, disease control, duration and time to response, and monitoring for adverse events. Participants are followed throughout the treatment period and up to 24 months to assess outcomes and safety.
CONDITIONS
Brief Title
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here